United Therapeutics

3 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in esrd (end-stage renal disease), pah, progressive pulmonary fibrosis. The ones with the nearest registered primary completion date still ahead:

• Dec 2026A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPhase 3Enrolling by invitationPAH
• Nov 2027Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)Phase 3RecruitingProgressive Pulmonary Fibrosis
• Oct 2028Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRDPhase 2RecruitingESRD (End-Stage Renal Disease)
• Nov 2029Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRDPhase 2RecruitingESRD (End-Stage Renal Disease)
• Dec 2029Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseasePhase 3Enrolling by invitationIdiopathic Pulmonary Fibrosis

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.